Radioactive drug trial offers new hope for Tough-to-Treat breast cancer

NCT ID NCT06590857

Summary

This early-stage trial is testing an experimental radioactive drug called RYZ101 for people with advanced ER+ breast cancer that has spread and stopped responding to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors in patients whose cancer cells show a specific marker on scans. It is for patients who have already tried other advanced therapies like antibody-drug conjugates or chemotherapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Facility

    Phoenix, Arizona, 85054, United States

  • Research Facility

    Irvine, California, 92618, United States

  • Research Facility

    San Diego, California, 92093, United States

  • Research Facility

    Santa Monica, California, 90404, United States

  • Research Facility

    Longmont, Colorado, 80504, United States

  • Research Facility

    Jacksonville, Florida, 32224, United States

  • Research Facility

    Atlanta, Georgia, 30322, United States

  • Research Facility

    Indianapolis, Indiana, 46202, United States

  • Research Facility

    Boston, Massachusetts, 02215, United States

  • Research Facility

    Detroit, Michigan, 48202, United States

  • Research Facility

    Rochester, Minnesota, 55905, United States

  • Research Facility

    St Louis, Missouri, 63130, United States

  • Research Facility

    Omaha, Nebraska, 68124, United States

  • Research Facility

    Albuquerque, New Mexico, 87109, United States

  • Research Facility

    Buffalo, New York, 14203, United States

  • Research Facility

    New York, New York, 10016, United States

  • Research Facility

    New York, New York, 10021, United States

  • Research Facility

    Cleveland, Ohio, 44195, United States

  • Research Facility

    Philadelphia, Pennsylvania, 19104, United States

  • Research Facility

    Pittsburgh, Pennsylvania, 15213, United States

  • Research Facility

    Dallas, Texas, 75246, United States

  • Research Facility

    Houston, Texas, 77024, United States

  • Research Facility

    Salt Lake City, Utah, 84132, United States

  • Research Facility

    Norfolk, Virginia, 23502, United States

  • Research Facility

    Seattle, Washington, 98109, United States

  • Research Facility

    Victoria, British Columbia, V8R 6V5, Canada

  • Research Facility

    Toronto, Ontario, M4N 3M5, Canada

  • Research Facility

    Toronto, Ontario, M5G 2M9, Canada

  • Research Facility

    Québec, Quebec, G1S 4L8, Canada

  • Research Facility

    Seoul, Seoul, 03080, South Korea

  • Research Facility

    Seoul, Seoul, 05505, South Korea

Conditions

Explore the condition pages connected to this study.